File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.

TitlePromoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.
Authors
Issue Date2003
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/
Citation
International Journal Of Oncology, 2003, v. 22 n. 5, p. 1025-1031 How to Cite?
AbstractOverexpression of cyclooxygenase-2 (COX-2) is associated with loss of apoptosis, enhancement of proliferation and tumorigenesis. The role of promoter methylation in the transcriptional silencing of cox-2 gene in human gastric cancer is less determined. We investigated 5 gastric cancer cell lines and 58 primary gastric carcinomas for the presence of promoter hypermethylation in cox-2 gene. Combined methylation-specific polymerase chain reaction analysis and bisulfite sequencing analysis revealed that the cox-2 promoter was methylated in 2 of the gastric cancer cell lines. Treatment with 5-aza-2'-deoxycytidine, a DNA methyltransferase inhibitor, induced COX-2 expression in the methylated gastric cancer cell line. Among the 58 primary gastric cancers, hypermethylation was detected in 25 (43.1%) cases. However, none of the normal gastric tissues showed methylation in cox-2. Promoter hypermethylation was associated with loss of protein expression as determined by immunostaining (p=0.005). Our results indicate that hypermethylation of the CpG island in the cox-2 gene is a major mechanism that mediates transcriptional silencing in a subset of gastric cancers. Thus, gastric cancers with methylation in cox-2 may not be good candidates for treatment with specific COX-2 inhibitors.
Persistent Identifierhttp://hdl.handle.net/10722/162711
ISSN
2015 Impact Factor: 3.018
2015 SCImago Journal Rankings: 1.270
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYu, Jen_US
dc.contributor.authorLeung, WKen_US
dc.contributor.authorLee, TLen_US
dc.contributor.authorTse, PCen_US
dc.contributor.authorTo, KFen_US
dc.contributor.authorSung, JJen_US
dc.date.accessioned2012-09-05T05:22:37Z-
dc.date.available2012-09-05T05:22:37Z-
dc.date.issued2003en_US
dc.identifier.citationInternational Journal Of Oncology, 2003, v. 22 n. 5, p. 1025-1031en_US
dc.identifier.issn1019-6439en_US
dc.identifier.urihttp://hdl.handle.net/10722/162711-
dc.description.abstractOverexpression of cyclooxygenase-2 (COX-2) is associated with loss of apoptosis, enhancement of proliferation and tumorigenesis. The role of promoter methylation in the transcriptional silencing of cox-2 gene in human gastric cancer is less determined. We investigated 5 gastric cancer cell lines and 58 primary gastric carcinomas for the presence of promoter hypermethylation in cox-2 gene. Combined methylation-specific polymerase chain reaction analysis and bisulfite sequencing analysis revealed that the cox-2 promoter was methylated in 2 of the gastric cancer cell lines. Treatment with 5-aza-2'-deoxycytidine, a DNA methyltransferase inhibitor, induced COX-2 expression in the methylated gastric cancer cell line. Among the 58 primary gastric cancers, hypermethylation was detected in 25 (43.1%) cases. However, none of the normal gastric tissues showed methylation in cox-2. Promoter hypermethylation was associated with loss of protein expression as determined by immunostaining (p=0.005). Our results indicate that hypermethylation of the CpG island in the cox-2 gene is a major mechanism that mediates transcriptional silencing in a subset of gastric cancers. Thus, gastric cancers with methylation in cox-2 may not be good candidates for treatment with specific COX-2 inhibitors.en_US
dc.languageengen_US
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/en_US
dc.relation.ispartofInternational journal of oncologyen_US
dc.subject.meshAdenocarcinoma - Enzymology - Genetics - Pathology - Surgeryen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBase Sequenceen_US
dc.subject.meshCyclooxygenase 2en_US
dc.subject.meshDna Methylationen_US
dc.subject.meshDna Primersen_US
dc.subject.meshFemaleen_US
dc.subject.meshGastrectomyen_US
dc.subject.meshGene Expression Regulation, Neoplasticen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshIsoenzymes - Geneticsen_US
dc.subject.meshMaleen_US
dc.subject.meshMembrane Proteinsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPolymerase Chain Reactionen_US
dc.subject.meshPromoter Regions, Geneticen_US
dc.subject.meshProstaglandin-Endoperoxide Synthases - Geneticsen_US
dc.subject.meshRna, Messenger - Geneticsen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshStomach Neoplasms - Enzymology - Genetics - Pathology - Surgeryen_US
dc.subject.meshTranscription, Geneticen_US
dc.subject.meshTumor Cells, Cultureden_US
dc.titlePromoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.en_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid12684668-
dc.identifier.scopuseid_2-s2.0-0042629619en_US
dc.identifier.volume22en_US
dc.identifier.issue5en_US
dc.identifier.spage1025en_US
dc.identifier.epage1031en_US
dc.identifier.isiWOS:000182165400011-
dc.publisher.placeGreeceen_US
dc.identifier.scopusauthoridYu, J=35351306800en_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridLee, TL=35292432600en_US
dc.identifier.scopusauthoridTse, PC=7005336892en_US
dc.identifier.scopusauthoridTo, KF=7101911940en_US
dc.identifier.scopusauthoridSung, JJ=35405352400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats